The Technical Analyst
Frequency Therapeutics [FREQ]
Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology
Frequency Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
8.54% $1.335
Last updated: 16 May 2022 @ 10:32 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 46.69 mill |
| EPS: | -2.47 |
| P/E: | 0.000 |
| Earnings Date: | Aug 10, 2022 |
| SharesOutstanding: | 34.98 mill |
| Avg Daily Volume: | 0.699 mill |
| RATING 2022-05-13 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.86 (189.01%) $2.52 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.176 ( +/- 14.31%) Range: 1.054 - 1.406 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-02-22 | Loose Christopher R. | Sell | 1 069 | Common Stock |
| 2022-02-22 | Pfreundschuh Peter P. | Sell | 1 542 | Common Stock |
| 2022-02-22 | Arnold Wendy S | Sell | 1 326 | Common Stock |
| 2022-02-22 | Mccubbin Quentin | Sell | 1 584 | Common Stock |
| 2022-02-22 | Lebel Carl | Sell | 1 069 | Common Stock |
| INSIDER POWER |
|---|
| 59.58 |
| Last 100 transactions |
| Buy: 1 716 343 | Sell: 430 853 |
Forecast:
12:11 - $1.317
Live Trading Signals (every 1 min)
Forecast
1: 10:41 - $1.337
Forecast 2: 11:31 - $1.342
Forecast 3: 12:11 - $1.317
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.335 (8.54% ) |
| Volume | 0.114 mill |
| Avg. Vol. | 0.699 mill |
| % of Avg. Vol | 16.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FREQ
257 Signals | Accuracy: 14.79% | Accuracy Buy: 10.94% | Accuracy Sell: 18.60%
Avg return buy: -0.51 % | Avg return sell: 0.24 %
$1 invested is now $0.52 or -48.36% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 09:36 | buy | $1.250 | N/A | Active |
|---|---|---|---|---|
| May 16 - 09:34 | sell | $1.231 | $1.250 @ May 16 - 09:35 | 1.58% |
| May 16 - 09:31 | buy | $1.270 | $1.231 @ May 16 - 09:34 | -3.11% |
| May 13 - 12:38 | sell | $1.290 | $1.270 @ May 16 - 09:30 | -1.55% |
| May 13 - 12:18 | buy | $1.285 | $1.290 @ May 13 - 12:37 | 0.39% |
| May 13 - 12:11 | sell | $1.270 | $1.280 @ May 13 - 12:17 | 0.79% |
| May 13 - 12:07 | buy | $1.280 | $1.270 @ May 13 - 12:10 | -0.78% |
| May 13 - 12:02 | sell | $1.270 | $1.280 @ May 13 - 12:06 | 0.79% |
| May 13 - 11:59 | buy | $1.280 | $1.270 @ May 13 - 12:02 | -0.78% |
| May 13 - 11:56 | sell | $1.270 | $1.280 @ May 13 - 11:58 | 0.79% |
FREQ
Frequency Therapeutics, Inc. engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. The company is headquartered in Woburn, Massachusetts and currently employs 37 full-time employees. The firm is focused on developing small molecule drugs that activate progenitor cells within the body to restore healthy tissue. The company uses its PCA technology to develop a pipeline of progenitor cell activators. The company focuses on various therapeutic areas, such as hearing loss, skin disorders, muscle regeneration, and gastrointestinal diseases. Its lead program, FX-322, activates the regrowth of sensory cells in the inner ear to treat chronic noise induced hearing loss.
Latest Press Releases
2022-03-15 07:30:00 - Press Release
Frequency Therapeutics Provides Business Updates And Reports Fourth Quarter And Full Year 2021 Financial Results
Lexington, mass.--(business wire)--frequency therapeutics, inc. (nasdaq: freq), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended december 31, 2021. “the year ahead has numerous milestones for frequency and our lead program fx-322, as we plan to complete enrollment and work toward a readout of
2021-12-09 07:30:00 - Press Release
Frequency Therapeutics Shares Results From Fx-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements In Noise
Lexington, mass.--(business wire)--frequency therapeutics, inc. (nasdaq: freq), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today shared the results from its fx-322-113 study, a placebo-controlled trial evaluating the administration of fx-322 in subjects with severe sensorineural hearing loss (snhl). in the study, fx-322 was associated with a hearing signal as shown by improvements by
2021-11-15 07:30:00 - Press Release
Frequency Therapeutics Provides Business Updates And Third Quarter 2021 Financial Results
Lexington, mass.--(business wire)--frequency therapeutics, inc. (nasdaq: freq), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced business updates and financial results for the third quarter ended september 30, 2021. “frequency has made significant operational progress throughout this year, highlighted by the initiation of a phase 2b study (fx-322-208) of fx-322, our lead pr
2021-11-09 07:30:00 - Press Release
Frequency Therapeutics Holds Virtual R&d Event Highlighting Clinical Advancement Of Fx-322, A New Potential Restorative Treatment For Hearing Loss And In Vivo Data For Its Remyelination Program In Multiple Sclerosis
Lexington, mass.--(business wire)--frequency therapeutics, inc. (nasdaq: freq), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today will host a virtual r&d event. the webcast can be accessed here. “we look forward to highlighting the extensive data supporting our phase 2b study (fx-322-208) in patients with sensorineural hearing loss (snhl), where we have seen clear clinical improve
2021-10-27 07:30:00 - Press Release
Frequency Therapeutics Virtual R&d Event To Detail Fx-322 Clinical Advances, A New Program For Hearing Restoration And In Vivo Data From Its Ms Remyelination Program
Lexington, mass.--(business wire)--frequency therapeutics, inc. (nasdaq: freq), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that the company will be hosting a virtual r&d event on november 9, 2021. at the event, frequency's clinical leaders will provide a detailed review of data from nearly 170 subjects dosed with fx-322. a rigorous statistical analysis of these cl
Latest News
2022-05-10 08:00:00 - PennyStocks
What to Know About Buying Penny Stocks on May 10th
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-22 07:30:00 - Business Wire
Frequency Therapeutics to Participate in B. Riley Securities' Neuro & Ophthalmology Investor Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose and Vice President of Discovery Biology Dr. Sanjay Magavi will participate in a fireside presentation at the B. Riley Securities' Neuro & Ophthalmology Conference on April 28, 2022 at 3:30 pm
2022-04-18 17:05:40 - PennyStocks
Best Penny Stocks to Buy in 2022? 3 to Watch in Late April
Why these penny stocks could be worth watching as April ends The post Best Penny Stocks to Buy in 2022? 3 to Watch in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-02-28 07:30:00 - Business Wire
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will participate in two upcoming investor conferences: Cowen 42nd Annual Health Care Conference: Corporate Panel Discussion - Auditory and Ophthalmology, March 7, 2022, 2:10 p.m. to 3:10 p.m. EST Oppe
2021-12-09 13:18:09 - Benzinga
Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise
Frequency Therapeutics Inc (NASDAQ: FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL). The Phase 1b study, FX-322, was associated with a hearing signal, as shown by improvements by four subjects in a sentence-in-noise test.
2021-11-15 13:55:14 - Zacks Investment Research
Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates
Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -32.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-09 10:19:48 - TechCrunch
Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs
In Frequency Therapeutics' short lifetime as a company, it's had its ups and downs. On Tuesday, during an R&D event day, the company unleashed a slew of announcements that add context to the development of a flagship hearing loss drug, and propose some directions.
2021-11-08 16:06:17 - Zacks Investment Research
Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for
Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-09-22 11:18:14 - Benzinga
Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors
Frequency Therapeutics Inc (NASDAQ: FREQ) has announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements. The patients were evaluated 8 to 12 months following initial dosing.
2021-09-22 07:30:00 - Business Wire
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore human function, today announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements when evaluated 8 to 12 months following initial dosing. Including the five initial r